Skip to content

Effect of Maca and maca compound product on patients with climacteric syndrome

Effect of Maca and maca compound product on patients with climacteric syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15007645
Enrollment
Unknown
Registered
2015-12-24
Start date
2016-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

climacteric syndrome

Interventions

maca group:Oral maca products, 2 pills/day for 3 months
maca compound product group:Oral maca compound products, 2 pills/day for 3 months

Sponsors

Department of Nutrition, Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) diagnosed with climacteric syndrome; (2) aged from 45 to 65; (3) without chronic metabolic diseases such as hypertension, diabetes; (4) informed consent and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) severe disease of heart or head; (2) combined with endocrine disease and mental illness; (2) take hormone in 3 months; (3) any factors not suitable for research determined by researchers.

Design outcomes

Primary

MeasureTime frame
laboratory assay;SOD;Serum malondialdehyde;Human body composition;blood vitamin;Kupperman’s Menopausal Index;Fatigue Scale-14;

Secondary

MeasureTime frame
Dietary intake;

Countries

China

Contacts

Public ContactLiu Yinghua
liuyinghua77@163.com+86 10-66937619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026